The viscosupplementation market is experiencing rapid growth driven by advancements in technology and innovative methodologies. Recent developments include next-generation hyaluronic acid injections, improved delivery systems, and regenerative medicine techniques like stem cell integration. These innovations enhance treatment efficacy for osteoarthritis, providing longer-lasting pain relief and improved joint function. The adoption of minimally invasive procedures and personalized treatment plans further propel market expansion. Increasing prevalence of osteoarthritis and rising awareness about non-surgical options contribute to the market's robust growth, making viscosupplementation a preferred choice for joint health management.
Data Bridge Market Research analyses that the Global Viscosupplementation Market size is growing with the CAGR of 8.5% in the forecast period of 2022 to 2029.
To know more about the study, visit: https://www.databridgemarketresearch.com/jp/reports/global-viscosupplementation-market
Below are the Top Five Viscosupplementation Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Johnson & Johnson Services, Inc.
|
Johnson & Johnson Services, Inc., a globally renowned healthcare company, operates in the viscosupplementation market primarily through its subsidiary, DePuy Synthes. DePuy Synthes offers a range of hyaluronic acid-based products designed to alleviate pain in osteoarthritis patients by improving joint lubrication and function. Their comprehensive product line, coupled with a strong global distribution network, positions them as a key player in the market. Additionally, their ongoing research and development efforts focus on enhancing the efficacy and safety of viscosupplementation treatments, solidifying their commitment to innovation and patient care in the musculoskeletal health sector.
|
|
Middle East and Africa, Europe, Asia-Pacific, America
|
In June 2022, Johnson & Johnson Services, Inc. presented new data from Phase 3 studies demonstrating patients treated with medicine achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis, dactylitis, spinal pain and disease severity endpoints irrespective of baseline characteristics. This has helped the company to showcase its progress.
|
|
2.
|
Bioventus
|
Bioventus is a medical device company specializing in orthobiologic solutions, including viscosupplementation. Their flagship product, DUROLANE, is a single-injection hyaluronic acid therapy aimed at providing long-lasting pain relief for osteoarthritis patients. Bioventus leverages advanced research to offer treatments that enhance joint mobility and quality of life. The company’s strong emphasis on clinical evidence and regulatory approvals underscores its commitment to safety and efficacy. Bioventus’s strategic partnerships and broad distribution channels enable it to maintain a significant presence in the viscosupplementation market, catering to the needs of patients and healthcare providers globally.
|
|
Middle East and Africa, Europe, Asia-Pacific, America
|
In September 2021, Bioventus, a leader in innovations for active healing, announced that the American Academy of Orthopaedic Surgeons (AAOS) recently released updated clinical practice guidelines (CPG) indicating that high molecular weight cross-linked hyaluronic treatments, including Bioventus treatment DUROLANE, showed statistically significant improvement in certain knee osteoarthritis (OA) patients. This has helped the company to showcase its progress in the field of viscosupplementation.
|
|
3.
|
Ferring B.V.
|
Ferring B.V., part of the Ferring Pharmaceuticals group, engages in the viscosupplementation market through its development and distribution of hyaluronic acid products for joint pain management. Known for its innovative approach and high-quality standards, Ferring’s viscosupplementation offerings aim to provide effective and sustained relief for osteoarthritis sufferers. The company’s dedication to research and patient-centric solutions is evident in its product portfolio and ongoing clinical studies. Ferring’s robust global presence and commitment to improving patient outcomes position it as a reliable entity in the viscosupplementation sector, addressing the unmet needs of the musculoskeletal community.
|
|
Middle East and Africa, Europe, Asia-Pacific, America
|
Ferring B.V. offers Hyaluronic Acid (HA) based viscosupplementation products for osteoarthritis treatment. Their portfolio includes injectable treatments aimed at restoring joint lubrication and reducing pain. Ferring's HA products, designed to mimic the body's natural synovial fluid, help enhance mobility and improve the quality of life for patients suffering from joint degeneration. Their innovative solutions emphasize safety, efficacy, and patient comfort, positioning them as a key player in the viscosupplementation market.
|
|
4.
|
Sanofi
|
Sanofi, a global biopharmaceutical leader, contributes to the viscosupplementation market through its portfolio of hyaluronic acid-based therapies aimed at treating osteoarthritis. With a strong focus on research and innovation, Sanofi develops products that provide effective pain relief and improve joint function. The company’s extensive distribution network and strategic collaborations enhance its market reach and accessibility. Sanofi’s commitment to high-quality standards and patient well-being is reflected in its rigorous clinical testing and approval processes, ensuring the safety and efficacy of its viscosupplementation products. This positions Sanofi as a trusted name in the management of joint health.
|
|
Middle East and Africa, Europe, Asia-Pacific, America
|
In May 2017, sanofi-aventis U.S. LLC and Regeneron Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) approval of Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have an inadequate response to one or more disease-modifying antirheumatic drugs. Kevzara is a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R) and has been shown to inhibit IL-6R mediated signaling. This has helped the company to work on further studies on the drug.
|
|
5.
|
Zimmer Biomet
|
Zimmer Biomet is a leading orthopedic company with a significant presence in the viscosupplementation market. The company offers a range of hyaluronic acid injections designed to alleviate pain and improve mobility in patients with osteoarthritis. Zimmer Biomet’s commitment to advancing musculoskeletal health is evident through its continuous investment in research and development. By combining innovative technology with clinical expertise, Zimmer Biomet provides solutions that enhance joint function and quality of life. The company’s strong market presence, supported by a global distribution network, ensures wide accessibility and trust among healthcare providers and patients in the viscosupplementation field.
|
|
Middle East and Africa, Europe, Asia-Pacific, America
|
In January 2019, Zimmer Biomet announced U.S. Food and Drug Administration 510(k) clearance of the ROSA Knee System for robotically-assisted total knee replacement surgeries. ROSA Knee features 3D pre-operative planning tools and real-time intraoperative data on soft-tissue and bone anatomy designed to improve bone cut accuracy and range of motion gap analysis to improve flexion and restoration of natural joint movement potentially. This has helped the company to research further on the system.
|
Conclusion
The viscosupplementation market is poised for substantial growth, driven by the rising prevalence of osteoarthritis and increasing awareness of non-surgical treatment options. Advances in hyaluronic acid-based products and a growing elderly population further bolster market expansion. Additionally, favorable reimbursement policies and a surge in demand for minimally invasive procedures present significant opportunities. As healthcare providers and patients seek effective, low-risk treatments, the market for viscosupplementation is expected to thrive, underscoring its vital role in improving joint function and quality of life for individuals with osteoarthritis.
